"Study Shows Benefit of Multiple Assessments of MRD in Multiple Myeloma" - Lauren Arcuri
A study published in American Journal of Hematology looked at whether using a combination of PET and MFC to evaluate minimal residual disease had a beneficial effect on progression-free and overall survival in 103 patients with newly diagnosed multiple myeloma. According to Joshua Richter, MD, assistant professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai, this study affirms the benefits of a multimodal approach for assessing MRD. He added, “Some patients only express the disease in the blood, while others only show it in the marrow, or only outside the marrow with extramedullary disease. The reality is that when we’re not comprehensive with these analyses, we can sometimes miss relapses.”
— Joshua Richter, MD, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai